Tegavivint Clinical Trials
6 recruitingDrug
Phase 16Phase 23
Showing 1–6 of 6 trials
Recruiting
Phase 1Phase 2
Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma
Colorectal Cancer (CRC)Metastatic Colorectal Carcinoma (mCRC)Adenomatous Polyposis Coli (APC) Gene Mutation+1 more
HonorHealth Research Institute126 enrolled1 locationNCT07463599
Recruiting
Phase 1
Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma
Refractory OsteosarcomaOsteosarcoma in ChildrenOsteosarcoma Recurrent+1 more
Emory University24 enrolled1 locationNCT07144254
Recruiting
Phase 1
Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma
Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRefractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRecurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type+6 more
Lapo Alinari18 enrolled1 locationNCT05755087
Recruiting
Phase 1Phase 2
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Ovarian CarcinomaColorectal CarcinomaMelanoma+19 more
Children's Oncology Group147 enrolled21 locationsNCT04851119
Recruiting
Phase 1
Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer
Metastatic Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8+1 more
Ohio State University Comprehensive Cancer Center24 enrolled1 locationNCT04780568
Recruiting
Phase 1Phase 2
A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma
Advanced Hepatocellular Carcinoma
Iterion Therapeutics178 enrolled8 locationsNCT05797805